Interaction of nerve agent antidotes with cholinergic systems

Current Medicinal Chemistry

Volumn 17, Issue 16, 2010, Pages 1708-1718

  Soukup, O ^a   Tobin, G ^b   Kumar, U K ^b   Binder, J ^c   Proska, J ^d   Jun, D ^e   Fusek, J ^a   Kuca, K ^a,e  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^d CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

^e UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acetylcholinesterase; Antidotes; Cholinergic system; Muscarinic receptors; Nerve agents; Nicotinic receptors; Ogranophosphates

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; 4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; ACETYLCHOLINESTERASE; ANTIDOTE; ATROPINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CYCLOSARIN; METHOCTRAMINE; METHYLPHOSPHONOTHIOIC ACID S (2 DIISOPROPYLAMINOETHYL) O ETHYL ESTER; OBIDOXIME; ORGANOPHOSPHORUS COMPOUND; OXIME DERIVATIVE; PIRENZEPINE; PRALIDOXIME; SARIN; SOMAN; TABUN; TRIMEDOXIME;

ARTICLE; CHOLINERGIC RECEPTOR BLOCKING; CHOLINERGIC SYSTEM; ENZYME ACTIVATION; HUMAN; INTOXICATION; NONHUMAN;

ACETYLCHOLINE; ANIMALS; ANTIDOTES; CHEMICAL WARFARE AGENTS; CHOLINESTERASES; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; RECEPTORS, CHOLINERGIC;

EID: 77953523413     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791111260     Document Type: Article

References (87)

1. Lüllmann, H.; Mohr, K.; Wehling, M. In Farmakologie a toxikologie, Grada: Praha, 2004; Vol. 2, pp. 83-123.
2. Furchgott, R.F. Introduction to EDRF research. J. Cardiovasc. Pharmacol., 1993, 22(Suppl 7), S1-2.
3. Widemaier, E.P.; Raff, H. Human Physiology of body function, McGraw-Hill: New York, 2004.
4. Tobin, G.; Giglio, D.; Lundgren, O. Muscarinic Receptor Subtypes in the Alimentary Tract. J. Physiol. Pharmacol., 2009, 60, 3-21.
5. Lindstrom, J. In Exploring the Vertebrate Central Cholinergic Nervous System, A.G. Karczmar, Editor, Springer: New York, 2007; Vol., pp. 211-213.
6. Eglen, R.M.; Nahorski, S.R. The muscarinic M-5 receptor: a silent or emerging subtype? Br. J. Pharmacol., 2000, 130, 13-21.
7. Bymaster, F.P.; Carter, P.A.; Yamada, M.; Gomeza, J.; Wess, J.; Hamilton, S.E.; Nathanson, N.M.; McKinzie, D.L.; Felder, C.C. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur. J. Neurosci., 2003, 17, 1403-10.
8. Levey, A.I. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci., 1993, 52, 441-8.
9. Tobin, G.; Giglio, D.; Gotrick, B. Studies of muscarinic receptor subtypes in salivary gland function in anaesthetized rats. Auton. Neurosci., 2002, 100, 1-9.
10. Giglio, D.; Tobin, G. Muscarinic Receptor Subtypes in the Lower Urinary Tract. Pharmacology, 2009, 83, 259-269.
11. Stengel, P.W.; Yamada, M.; Wess, J.; Cohen, M.L. M(3)-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2002, 282, R1443-9.
12. Elhusseiny, A.; Cohen, Z.; Olivier, A.; Stanimirovic, D.B.; Hamel, E. Functional acetylcholine muscarinic receptor subtypes in human brain microcirculation: identification and cellular localization. J. Cereb. Blood Flow Metab., 1999, 19, 794-802.
13. Bymaster, F.P.; McKinzie, D.L.; Felder, C.C.; Wess, J. Use of M1M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem. Res., 2003, 28, 437-42.
14. Radic, Z.; Taylor, P. in Toxicology of organophospate & carbamate compounds, R. Gupta, Editor, Elsevier Academic Press: London, 2006; pp. 161-186.
15. Adler, M.; Manley, H.A.; Purcell, A.L.; Deshpande, S.S.; Hamilton, T.A.; Kan, R.K.; Oyler, G.; Lockridge, O.; Duysen, E.G.; Sheridan, R.E. Reduced acetylcholine receptor density, morphological remodeling, and butyrylcholinesterase activity can sustain muscle function in acetylcholinesterase knockout mice. Muscle Nerve, 2004, 30, 317-327.
16. Greenspan, R.J.; Finn, J.A.; Hall, J.C. Acetylcholinesterase Mutants in Drosophila and Their Effects on the Structure and Function of the Central Nervous-System. J. Comp. Neurol., 1980, 189, 741774.
17. Gupta, A.; Gupta, R. A survey of plants for presence of cholinesterase activity. Phytochemistry, 1997, 46, 827-831.
18. Gupta, A.; Vijayaraghavan, M.R.; Gupta, R. The presence of cholinesterase in marine algae. Phytochemistry, 1998, 49, 1875-1877.
19. [19] Galagan, J.E.; Calvo, S.E.; Borkovich, K.A.; Selker, E.U.; Read, N.D.; Jaffe, D.; FitzHugh, W.; Ma, L.J.; Smirnov, S.; Purcell, S.; Rehman, B.; Elkins, T.; Engels, R.; Wang, S.G.; Nielsen, C.B.; Butler, J.; Endrizzi, M.; Qui, D.Y.; Ianakiev, P.; Pedersen, D.B.; Nelson, M.A.; Werner-Washburne, M.; Selitrennikoff, C.P.; Kinsey, J.A.; Braun, E.L.; Zelter, A.; Schulte, U.; Kothe, G.O.; Jedd, G.; Mewes, W.; Staben, C.; Marcotte, E.; Greenberg, D.; Roy, A.; Foley, K.; Naylor, J.; Stabge-Thomann, N.; Barrett, R.; Gnerre, S.; Kamal, M.; Kamvysselis, M.; Mauceli, E.; Bielke, C.; Rudd, S.; Frishman, D.; Krystofova, S.; Rasmussen, C.; Metzenberg, R.L.; Perkins, D.D.; Kroken, S.; Cogoni, C.; Macino, G.; Catcheside, D.; Li, W.X.; Pratt, R.J.; Osmani, S.A.; DeSouza, C.P.C.; Glass, L.; Orbach, M.J.; Berglund, J.A.; Voelker, R.; Yarden, O.; Plamann, M.; Seller, S.; Dunlap, J.; Radford, A.; Aramayo, R.; Natvig, D.O.; Alex, L.A.; Mannhaupt, G.; Ebbole, D.J.; Freitag, M.; Paulsen, I.; Sachs, M.S.; Lander, E.S.; Nusbaum, C.; Birren, B. The genome sequence of the filamentous fungus Neurospora crassa. Nature, 2003, 422, 859-868.
20. Raoult, D.; Audic, S.; Robert, C.; Abergel, C.; Renesto, P.; Ogata, H.; La Scola, B.; Suzan, M.; Claverie, J.M. The 1.2-megabase genome sequence of mimivirus. Science, 2004, 306, 1344-1350.
21. Sussman, J.L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic-Structure of Acetylcholinesterase from Torpedo-Californica - a Prototypic Acetylcholine-Binding Protein. Science, 1991, 253, 872-879.
22. Harel, M.; Quinn, D.M.; Nair, H.K.; Silman, I.; Sussman, J.L. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. J. Am. Chem. Soc., 1996, 118, 2340-2346.
23. Wilson, I.B.; Bergmann, F. Acetylcholinesterase.8. Dissociation Constants of the Active Groups. J. Biol. Chem., 1950, 186, 683-692.
24. Radic, Z.; Taylor, P. Interaction kinetics of reversible inhibitors and substrates with acetylcholinesterase and its fasciculin 2 complex. J. Biol. Chem., 2001, 276, 4622-4633.
25. Rosenberry, T.L.; Mallender, W.D.; Thomas, P.J.; Szegletes, T. A steric blockade model for inhibition of acetylcholinesterase by peripheral site ligands and substrate. Chem-Biol. Interact., 1999, 120, 85-97.
26. Barak, D.; Ordentlich, A.; Kaplan, D.; Barak, R.; Mizrahi, D.; Kronman, C.; Segall, Y.; Velan, B.; Shafferman, A. Evidence for PN bond scission in phosphoroamidate nerve agent adducts of human acetylcholinesterase. Biochemistry, 2000, 39, 1156-1161.
27. Bajgar, J. In Vojenska toxikologie, Patocka, J. Ed. Grada: Praha, 2004; pp. 30-44.
28. Nachon, F.; Asojo, O.A.; Borgstahl, G.E.O.; Masson, P.; Lockridge, O. Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: The crystal structure suggests two alternative mechanisms of aging. Biochemistry, 2005, 44, 1154-1162.
29. Watson, A.; Bakshi, K.; Opresko, D.; Young, R.; Hauschild, V.; King, J. in Toxicology of organophosphate & carbamate compounds, A. Gupta, Editor, Elsevier Academic Press: London, 2006; pp. 5-24.
30. Rao, K.S.; Aracava, Y.; Rickett, D.L.; Albuquerque, E.X. Noncompetitive Blockade of the Nicotinic Acetylcholine Receptor-Ion Channel Complex by an Irreversible Cholinesterase Inhibitor. J. Pharmacol. Exp. Ther., 1987, 240, 337-344.
31. Aas, P.; Veiteberg, T.A.; Fonnum, F. Acute and subacute inhalation of an organophoshpate induce alteration of cholinergic muscarinic receptors. Biochem. Pharmacol., 1987, 36, 1261-1266.
32. Kassa, J.; Kuca, K.; Cabal, J.; Paar, M. A comparison of the efficacy of new asymmetric bispyridinium oximes (K027, K048) with currently available oximes against tabun by in vivo methods. J. Toxicol. Environ. Health., 2006, 69, 1875-82.
33. Koplovitz, I.; Stewart, J.R. A comparison of the efficacy of HI6 and 2-PAM against soman, tabun, sarin, and VX in the rabbit. Toxicol. Lett., 1994, 70, 269-79.
34. Puu, G.; Artursson, E.; Bucht, G. Reactivation of nerve agent inhibited human acetylcholinesterases by HI-6 and obidoxime. Biochem. Pharmacol., 1986, 35, 1505-10.
35. Jokanovic, M.; Maksimovic, M.; Kilibarda, V.; Jovanovic, D.; Savic, D. Oxime-induced reactivation of acetylcholinesterase inhibited by phosphoramidates. Toxicol. Lett., 1996, 85, 35-9.
36. Kassa, J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J. Toxicol. Clin. Toxicol., 2002, 40, 803-16.
37. Bajgar, J. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem., 2004, 38, 151-216.
38. Kassa, J.; Bajgar, J. Comparison of the Efficacy of Hi-6 and Obidoxime against Cyclohexyl Methyl-Phosphonofluoridate (Gf) in Rats. Hum. Exp. Toxicol., 1995, 14, 923-928.
39. Anderson, D.R.; Harris, L.W.; Woodard, C.L.; Lennox, W.J. The Effect of Pyridostigmine Pretreatment on Oxime Efficacy against Intoxication by Soman or Vx in Rats. Drug Chem. Toxicol., 1992, 15, 285-294.
40. Kim, Y.B.; Cheon, K.C.; Hur, G.H.; Phi, T.S.; Choi, S.J.; Hong, D.; Kang, J.K. Effects of combinational prophylactics composed of physostigmine and procyclidine on soman-induced lethality, seizures and brain injuries. Environ. Toxicol. Pharmacol., 2002, 11, 15-21.
41. Albuquerque, E.X.; Aracava, Y.; Cintra, W.M.; Brossi, A.; Schonenberger, B.; Deshpande, S.S. Structure-activity relationship of reversible cholinesterase-inhibitors - activation, channel blockade and stereospecificity of the nicotinic acetylcholine-receptor ion channel complex. Braz. J. Med. Biol. Res., 1988, 21, 1173-1196.
42. Patocka, J.; Jun, D.; Bajgar, J.; Kuca, K. Prophylaxis against nerve agent intoxications. Defence Sci. J., 2006, 56, 775-784.
43. Cowan, J.; Sinton, C.M.; Varley, A.W.; Wians, F.H.; Haley, R.W.; Munford, R.S. Gene therapy to prevent organophosphate intoxication. Toxicol. Appl. Pharmacol., 2001, 173, 1-6.
44. Gupta, R.C.; Dettbarn, W.D. Potential of Memantine, DTubocurarine, and Atropine in Preventing Acute Toxic Myopathy Induced by Organophosphate Nerve Agents - Soman, Sarin, Tabun and Vx. Neurotoxicology, 1992, 13, 649-661.
45. Cowan, F.M.; Shih, T.M.; Lenz, D.E.; Madsen, J.M.; Broomfield, C.A. Hypothesis for synergistic toxicity of organophosphorus poisoning-induced cholinergic crisis and anaphylactoid reactions. J. Appl. Toxicol., 1996, 16, 25-33.
46. Kuca, K.; Jun, D.; Musilek, K.; Bajgar, J. Reactivators of TabunInhibited Acetylcholinesterase: Structure-Biological Activity Relationship. Frontiers Drug Des. Discov., 2007, 381-394.
47. Koplovitz, I.; Schulz, S.; Railer, R.; Sigler, M.; Kelleher, C.; Shutz, M. The effect of atropine dosage on the efficacy of other pretreatment and treatment medical countermeasures for nerve agent intoxication. Toxicology, 2007, 233, 232-233.
48. Kassa, J.; Frankova, K.; Hoder, P.; Patocka, J. A comparison of the efficacy of cholinolytics atropine and biperiden (Akineton(R)) in combination with HI-6 on cholinergic and stressogenic effects of soman in rats. Homeostasis Health. Dis., 1996, 37, 135-136.
49. Rousseaux, C.G.; Dua, A.K. Pharmacology of HI-6, an H-series oxime. Can. J. Physiol. Pharmacol., 1989, 67, 1183-9.
50. Krummer, S.; Thiermann, H.; Worek, F.; Eyer, P. Equipotent cholinesterase reactivation in vitro by the nerve agent antidotes HI 6 dichloride and HI 6 dimethanesulfonate. Arch. Toxicol., 2002, 76, 589-595.
51. Kassa, J.; Jun, D.; Kuca, K.; Bajgar, J. Comparison of reactivating and therapeutic efficacy of two salts of the oxime HI-6 against tabun, soman and cyclosarin in rats. Basic Clin. Pharmacol., 2007, 101, 328-332.
52. Kuca, K.; Musilek, K.; Stodulka, P.; Marek, J.; Hanusova, P.; Jun, D.; Hrabinova, M.; Kassa, J.; Dolezal, B. Twelve different HI-6 salts and their potency to reactivate cyclosarin inhibited AChE in vitro. Letters Drug Des. Discov., 2007, 4, 510-512.
53. Kusic, R.; Boskovic, B.; Vojvodic, V.; Jovanovic, D. Hi-6 in man blood-levels, urinary-excretion, and tolerance after intramuscular administration of the oxime to healthy-volunteers. Fund. Appl. Toxicol., 1985, 5, S89-S97.
54. Sidell, F.R.; Groff, W.A. Intramuscular and intravenous administration of small doses of 2-pyridinium aldoxime methochloride to man. J. Pharm. Sci., 1971, 60, 1224.
55. Sidell, F.R.; Groff, W.A. Toxogonin - Blood Levels and Side Effects after Intramuscular Administration in Man. J. Pharm. Sci., 1970, 59, 793-&.
56. Dawson, R.M. Review of oximes available for treatment of nerve agent poisoning. J. Appl. Toxicol., 1994, 14, 317-331,
57. Calic, M.; Vrdoljak, A.L.; Radic, M.; Jelic, D.; Jun, D.; Kuca, K.; Kovarik, Z. In vitro and in vivo evaluation of pyridinium oximes: Mode of interaction with acetylcholinesterase, effect on tabun- and soman-poisoned mice and their cytotoxicity. Toxicology, 2006, 219, 85-96.
58. Antonijevic, B.; Stojiljkovic, M.P. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin. Med. Res., 2006, 5, 71-82.
59. Melchers, B.P.; Philippens, I.H.; Wolthuis, O.L. Efficacy of HI-6 and HLo-7 in preventing incapacitation following nerve agent poisoning. Pharmacol. Biochem. Behav., 1994, 49, 781-8.
60. Vanhelden, H.P.M.; Vanderwiel, H.J.; Delange, J.; Busker, R.W.; Melchers, B.P.C.; Wolthuis, O.L. Therapeutic Efficacy of Hi-6 in Soman-Poisoned Marmoset Monkeys. Toxicol. Appl. Pharmacol., 1992, 115, 50-56.
61. Hamilton, M.G.; Lundy, P.M. HI-6 therapy of soman and tabun poisoning in primates and rodents. Arch. Toxicol., 1989, 63, 144-9.
62. Busker, R.W.; Zijlstra, J.J.; Vanderwiel, H.J.; Melchers, B.P.C.; Vanhelden, H.P.M. Organophosphate poisoning - a method to test therapeutic effects of oximes other than acetylcholinesterase reactivation in the rat. Toxicology, 1991, 69, 331-344.
63. Vanhelden, H.P.M.; Vanderwiel, H.J.; Zijlstra, J.J.; Melchers, B.P.C.; Busker, R.W. Comparison of the therapeutic effects and pharmacokinetics of Hi-6, Hlo-7, Hgg-12, Hgg-42 and obidoxime following non-reactivatable acetylcholinesterase inhibition in rats. Arch. Toxicol., 1994, 68, 224-230.
64. van Helden, H.P.; Busker, R.W.; Melchers, B.P.; Bruijnzeel, P.L. Pharmacological effects of oximes: how relevant are they? Arch. Toxicol., 1996, 70, 779-86.
65. Clement, J.G. Pharmacological Actions of Hs-6, an Oxime, on the Neuromuscular-Junction. Eur. J. Pharmacol., 1979, 53, 135-141.
66. Kloog, Y.; Sokolovsky, M. Bisquaternary pyridinium oximes as allosteric inhibitors of rat brain muscarinic receptors. Mol. Pharmacol., 1985, 27, 418-28.
67. Fossier, P.; Baux, G.; Poulain, B.; Tauc, L. Receptor-mediated presynaptic facilitation of quantal release of acetylcholine induced by pralidoxime in aplysia. Cell Mol. Neurobiol., 1990, 10, 383-404.
68. Inns, R.H.; Leadbeater, L. The Efficacy of Bispyridinium Derivatives in the Treatment of Organophosphonate Poisoning in the Guinea-Pig. J. Pharm. Pharmacol., 1983, 35, 427-433.
69. Loke, W.K.; Sim, M.K.; Go, M.L. O-Substituted derivatives of pralidoxime: muscarinic properties and protection against soman effects in rats. Eur. J. Pharmacol., 2002, 442, 279-87.
70. Tattersall, J.E. Ion channel blockade by oximes and recovery of diaphragm muscle from soman poisoning in vitro. Br. J. Pharmacol., 1993, 108, 1006-15.
71. Lundy, P.M.; Tremblay, K.P. Ganglion blocking properties of some bispyridinium soman antagonists. Eur. J. Pharmacol., 1979, 60, 47-53.
72. Kirsch, D.M.; Weger, N. Effects of the bispyridinium compounds Hgg12, Hgg42, and obidoxime on synaptic transmission and Nad(P)H-fluorescence in the superior cervical-ganglion of the rat invitro. Arch. Toxicol., 1981, 47, 217-232.
73. Broomfield, C.; Dembure, I.J.; Cuculis, J. Binding of soman antidotes to acetylcholine-receptors. Biochem. Pharmacol., 1987, 36, 1017-1022.
74. Alkondon, M.; Rao, K.S.; Albuquerque, E.X. Acetylcholinesterase reactivators modify the functional properties of the nicotinic acetylcholine receptor ion channel. J. Pharmacol. Exp. Ther., 1988, 245, 543-56.
75. Shaw, K.P.; Aracava, Y.; Akaike, A.; Daly, J.W.; Rickett, D.L.; Albuquerque, E.X. The Reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex. Mol. Pharmacol., 1985, 28, 527-538.
76. Kuhnen-Clausen, D.; Hagedorn, I.; Gross, G.; Bayer, H.; Hucho, F. Interactions of bisquaternary pyridine salts (H-oximes) with cholinergic receptors. Arch. Toxicol., 1983, 54, 171-9.
77. Amitai, G.; Kloog, Y.; Balderman, D.; Sokolovsky, M. Interaction of Bis-Pyridinium Oximes with Mouse-Brain Muscarinic Receptor. Biochem. Pharmacol., 1980, 29, 483-488.
78. Reithmann, C.; Berger, H.J.; Hilf, G.; Werdan, K. The oxime hgg12 as a muscarinic acetylcholine-receptor antagonist without intrinsic activity in cardiac membranes. Arch. Toxicol., 1991, 65, 518523.
79. Grossmuller, M.; Antony, J.; Trankle, C.; Holzgrabe, U.; Mohr, K. Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist. Naunyn Schmiedebergs Arch. Pharmacol., 2006, 372, 267-76.
80. Proska, J.; Tucek, S. Competition between positive and negative allosteric effectors on muscarinic receptors. Mol. Pharmacol., 1995, 48, 696-702.
81. Tucek, S.; Proska, J. Allosteric modulation of muscarinic acetylcholine-receptors. Trends Pharmacol. Sci., 1995, 16, 205-212.
82. Christopoulos, A.; Lanzafame, A.; Mitchelson, F. Allosteric interactions at muscarinic cholinoceptors. Clin. Exp. Pharmacol. Physiol., 1998, 25, 185-194.
83. Ellis, J.; Seidenberg, M. 2 Allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol.Pharmacol., 1992, 42, 638-641.
84. Lee, N.H.; Elfakahany, E.E. Allosteric antagonists of the muscarinic acetylcholine-receptor. Biochem. Pharmacol., 1991, 42, 199-205.
85. Schoene, K.; Steinhanses, J.; Oldiges, H. Reactivation of soman inhibited acetylcholinesterase in vitro and protection against soman in vivo by bispyridinium-2-aldoximes. Biochem. Pharmacol., 1983, 32, 1649-51.
86. Reithmann, C.; Berger, H.J.; Hilf, G.; Werdan, K. The oxime HGG12 as a muscarinic acetylcholine receptor antagonist without intrinsic activity in cardiac membranes. Arch. Toxicol., 1991, 65, 518-23.
87. Loke, W.K.; Sim, M.K.; Go, M.L. Novel neuroprotective effects with O-benzyl derivative of pralidoxime in soman-intoxicated rodents. Eur. J. Pharmacol., 2005, 521, 59-69.